Featured Research

from universities, journals, and other organizations

University Of Pittsburgh Medical Center Discharges Its First Patient With Permanent Artificial Heart

Date:
July 21, 2004
Source:
University Of Pittsburgh Medical Center
Summary:
The University of Pittsburgh Medical Center (UPMC) is discharging its first patient who was successfully implanted, on July 2, with the Heartmate XVE™ Left Ventricular Assist System (LVAS). It was implanted as a permanent implant in lieu of a heart transplant, as opposed to the traditional use for this type of device.

Credit: Image courtesy of McGowan Institute for Regenerative Medicine / University of Pittsburgh Medical Center

PITTSBURGH, July 20 – The University of Pittsburgh Medical Center (UPMC) today is discharging its first patient who was successfully implanted, on July 2, with the Heartmate XVE™ Left Ventricular Assist System (LVAS). It was implanted as a permanent implant in lieu of a heart transplant, as opposed to the traditional use for this type of device.

The patient, 58-year-old John Didion, has recovered well enough to be discharged to his home in Allison Park, Pa.

The Heartmate XVE (LVAS) is a long-term permanent assist device approved by the U.S. Food and Drug Administration (FDA) for this so-called destination therapy in patients with end-stage heart failure who, despite receiving optimal treatment, have a life expectancy of less than two years and are not viable candidates for heart transplantation.

"I never thought this day would be possible," said Mr. Didion. "I am so grateful to the dedicated staff at UPMC. If it weren't for them, I wouldn't be here today. I am living proof that this works."

Last fall, UPMC was among the first centers to receive approval from the Centers for Medicare & Medicaid Services (CMS) to implant left ventricular assist systems approved by the FDA, and UPMC is only one of two approved centers in western Pennsylvania to implant the Heartmate XVE.

"We are pleased to be able to bring this new technology and therapeutic approach to our patients," said Robert L. Kormos, M.D., professor of surgery at the University of Pittsburgh School of Medicine and director of UPMC's Artificial Heart and Heart Transplant programs. "Heart transplantation is still the best option for long-term survival, but unfortunately, is not feasible for everyone. This new therapy allows us to return people to productive lives at home as an alternative to dying from end-stage congestive heart failure."

"The Heartmate XVE has been developed to be a viable therapy and is giving new hope to people," said Dennis McNamara, M.D., associate professor of medicine at the University of Pittsburgh School of Medicine and director of the Heart Failure/Transplantation Program at the UPMC Cardiovascular Institute. "As the technology improves, this may someday, in conjunction with heart transplantation and other new therapies, help us to provide a full spectrum of choices for heart failure therapy."

UPMC also is part of an elite 21-member national cardiac center consortium, known as Heart Hope, and among the first to implement advance practice guidelines for the permanent implantation of heart pumps as destination therapy. With nearly five million Americans living with heart failure, it is estimated that as many as 100,000 patients a year in the United States could benefit from destination therapy, bringing them new hope for increased survival and quality of life.

These new guidelines, which were created by a subset of the Heart Hope Centers, will help improve patient outcomes with life-saving benefits. Their experience has enabled them to identify and address even the smallest nuances in care that can make a significant improvement in patient's survival and hospital discharge rates. There are an estimated 550,000 new cases of heart failure diagnosed each year. This number continues to increase, emphasizing the importance of facilitating these guidelines to support the continued improvement of patient outcomes.

As the use of destination therapy expands, the long-term vision for mechanical support is to assist the heart while it repairs itself using novel new cellular therapies. These goals include promoting recovery from the mechanical effects of heart failure and availability as a viable replacement option when all other choices fail. These goals encompass the broader mission of the McGowan Institute for Regenerative Medicine and are a result of the collaboration among scientists, engineers and clinicians.

UPMC's Artificial Heart Program, in collaboration with UPMC's Congestive Heart Failure Program, is one of the most experienced and active in the United States. The program was established in 1985 and has supported nearly 300 patients on various assist devices for a period of time that equates to more than 65 patient-years. It often serves as both a proving ground for manufacturers and a training center for surgeons from around the world. Devices that UPMC has used over the years include the Jarvik/Cardiowest Total Artificial Heart, Novacor Left Ventricular Assist Device (LVAD), Thoratec VAD and HeartMate I and recently the new miniaturized rotary blood pump, the Heartmate II.

Known also for its aggressive work to enable patients on devices to be discharged to the home setting, UPMC was the first center to discharge a patient still on a device to await a human donor outside the hospital. Based on UPMC's experience, the FDA later allowed patients implanted with the Novacor to be discharged to their homes to await heart transplant. It was the first in the country to develop an experienced bioengineering team, called Vital Engineering, which provides local and national support for patients on these types of devices.

###

For more information about the cardiac programs at UPMC, the HeartMate or destination therapy, visit http://newsbureau.upmc.com/MediaKits/McGowanMain.htm. For a complete list of Medicare approved facilities, go to http://www.cms.hhs.gov/coverage/lvadfacility.asp.


Story Source:

The above story is based on materials provided by University Of Pittsburgh Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

University Of Pittsburgh Medical Center. "University Of Pittsburgh Medical Center Discharges Its First Patient With Permanent Artificial Heart." ScienceDaily. ScienceDaily, 21 July 2004. <www.sciencedaily.com/releases/2004/07/040721090749.htm>.
University Of Pittsburgh Medical Center. (2004, July 21). University Of Pittsburgh Medical Center Discharges Its First Patient With Permanent Artificial Heart. ScienceDaily. Retrieved September 23, 2014 from www.sciencedaily.com/releases/2004/07/040721090749.htm
University Of Pittsburgh Medical Center. "University Of Pittsburgh Medical Center Discharges Its First Patient With Permanent Artificial Heart." ScienceDaily. www.sciencedaily.com/releases/2004/07/040721090749.htm (accessed September 23, 2014).

Share This



More Health & Medicine News

Tuesday, September 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Liberia Pleads for Help to Fight Ebola

Liberia Pleads for Help to Fight Ebola

AP (Sep. 22, 2014) Liberia's finance minister is urging the international community to quickly follow through on pledges of cash to battle Ebola. Bodies are piling up in the capital Monrovia as the nation awaits more help. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Ebola Doctor Says Border Controls Critical

Ebola Doctor Says Border Controls Critical

AP (Sep. 22, 2014) A Florida doctor who helped fight the expanding Ebola outbreak in West Africa says the disease can be stopped, but only if nations quickly step up their response and make border control a priority. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Global Ebola Aid Increasing But Critics Say It's Late

Global Ebola Aid Increasing But Critics Say It's Late

Newsy (Sep. 21, 2014) More than 100 tons of medical supplies were sent to West Africa on Saturday, but aid workers say the global response is still sluggish. Video provided by Newsy
Powered by NewsLook.com
Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins